This site is intended for Great Britain healthcare professionals only 

Visit Pfizer Medical site
Search

Menu

Close

Sign In or RegisterLog Out
Pfizer MedicinesTherapy AreasExplore ContentEventsVideosMaterialsLet’s ConnectStock Hub

Menu

Close

AboutAboutHow Cibinqo worksIntroducing CibinqoMOA OverviewPatient ProfilesPatient Profiles OverviewPatient Profile 1Patient Profile 2Patient Profile 3Patient Profile 4EfficacyEfficacyClinical EfficacyStudy OverviewJADE COMPAREJADE MONOJADE REGIMENJADE TEENJADE EXTENDSafety
Safety
 
Safety
 
Safety Guidance
DosingDosingDosingOral once-daily dosingPractical ConsiderationsSupport & ResourcesSupport & ResourcesHCP ResourcesMedicine Evidence InformationPatient ResourcesVideos
Materials

Information on how to access Cibinqo® (abrocitinib) prescribing information and adverse event reporting can be found at the bottom of the page.

JADE COMPARECibinqo efficacy in combination with medicated topical therapy vs placebo and dupilumab1,2​​​​​​​

This pivotal Phase III clinical trial evaluated the efficacy and safety of Cibinqo in combination with medicated topical therapy vs placebo in 838 patients with moderate-to-severe AD, with a direct head-to-head comparison with dupilumab as an active comparator for itch relief at Week 2.1,2

STUDY DESIGN1,2

*Patients used non-medicated emollient twice daily, starting at least 7 days before randomisation and continued throughout the trial.
Patients used medicated topical therapy (once daily) such as low- or medium-potency topical corticosteroids, calcineurin inhibitors, or PDE4 inhibitors, starting on Day 1 and as per protocol guidance, to treat active lesions during the study. 

Co-primary endpoints:
  • EASI-75 response at Week 12 vs placebo (defined as a 75% improvement in EASI score from baseline)
  • ​​​​​​​IGA 0/1 response with ≥2-point improvement at Week 12 vs placebo
Secondary endpoints:
    • PP-NRS4 response of either dose of Cibinqo vs dupilumab and placebo at Week 2 (defined as an improvement of ≥4 points from baseline in the severity of PP-NRS)
    • ​​​​​​​IGA 0/1 response with ≥2-point improvement and EASI-75 response at Week 16 vs placebo
    • EASI-90 response at Week 12 vs placebo
    • Score on the Patient-Oriented eczema Measure (POEM; scores range from 0–28 with higher scores indicating greater severity)
    • Score on the Dermatology Life Quality Index (DLQI; scores range from 0–30 with higher scores indicating greater impairment)
    • Change in the subjective assessment of sleep loss on the SCOring Atopic Dermatitis (SCORAD; scores range from 0–103 with higher scores indicating greater severity) sleep loss subscale

    The primary analysis of efficacy was performed in the modified intention-to-treat-population, which included all the patients who had undergone randomisation and received at least 1 dose of a trial drug or placebo.

    Baseline characteristics*2
    Scroll left to view table

    Cibinqo 200 mg, OD (N=226) Cibinqo 100 mg, OD (N=238) Dupilumab 300 mg, every other week (N=242) ​​​​​​ Placebo (N=131) ​​​​​​​​​​​​​
    Age, years ​​​​​​​ 38.8 ±14.5 37.3 ±14.8 37.1 ±14.6 37.1 ±14.6
    Female sex, n (%) 122 (54.0) 118 (49.6) 134 (55.4) 54 (41.2)
    Race, n (%)
    • White
    • Black
     Asian
     Other
     
    ​​​​​​​• 161 (71.2)
     9 (4.0)
    ​​​​​​​• 53 (23.5)
    ​​​​​​​• 3 (1.3)
     
    ​​​​​​​• 161 (71.2)
     9 (4.0)
    ​​​​​​​• 53 (23.5)
    ​​​​​​​• 3 (1.3)

     176 (72.7)
     14 (5.8)
    ​​​​​​​• 46 (19.0)
    ​​​​​​​• 6 (2.5)
     
    ​​​​​​​• 87 (66.4)
     6 (4.6)
    ​​​​​​​• 31 (23.7)
    ​​​​​​​• 7 (5.3)
    Duration of AD, years 23.4 ±15.6 22.7 ±16.3 22.8 ±14.8 21.4 ±14.4
    IGA score, n (%)
    • 0, clear
    • 1, almost clear
     2, mild
     3, moderate
     ​​​​​​​4, severe
     
    ​​​​​​​• 0
     0
    ​​​​​​​• 0
    ​​​​​​​• 138 (61.1)
     88 (38.9)
     
    ​​​​​​​• 0
     0
    ​​​​​​​• 0
    ​​​​​​​• 138 (61.1)
     88 (38.9)
     
    ​​​​​​​• 0
     0
    ​​​​​​​• 0
    ​​​​​​​• 138 (61.1)
     88 (38.9)
     
    ​​​​​​​• 0
     0
    ​​​​​​​• 0
    ​​​​​​​• 138 (61.1)
     88 (38.9)
    EASI score 32.1 ±13.1 30.3 ±13.5 30.4 ±12.0 31.0 ±12.6
    BSA involvement, % 50.8 ±23.0 50.8 ±23.0 46.5 ±22.1 48.9 ±24.9
    PP-NRS score 7.6 ±1.5 7.1 ±1.7 7.3 ±1.7 7.1 ±1.8
    SCORAD score 69.3 ±12.7 66.8 ±13.8 67.9 ±11.4 67.9 ±12.0
    POEM score 21.5 ±5.3 20.9 ±5.3 20.9 ±5.3 20.4 ±6.1
    DLQI score 16.3 ±6.6 15.5 ±6.4 15.5 ±6.4 15.2 ±6.9
    ​​​​​​​​​​​​​​Coexisting medical conditions
    • Asthma
    • Allergic conjunctivitis
    • ​​​​​​​Food allergy
     
    ​​​​​​​• 82 (36.3)
    • 18 (8.0)
    ​​​​​​​• 39 (17.3)

     
     
    ​​​​​​​• 79 (33.2)
     21 (8.8)
     ​​​​​​​36 (15.1)
     
    ​​​​​​​• 75 (31.0)
     26 (10.7)
     ​​​​​​​36 (14.9)
     
    ​​​​​​​• 48 (36.6)
     14 (10.7)
     ​​​​​​​14 (10.7)

    *Plus-minus values are means ±SD. Percentages may not total 100 due to rounding.​​​​​​​
    Race was reported by the patients.

    Inclusion/exclusion criteria2,3INCLUSION CRITERIA2
    • ≥18 years of age
    • Clinically diagnosed with chronic AD for ≥1 year, confirmed by Hanifin and Rajka criteria of AD at the screening and baseline visits. Criteria for AD diagnosis include ≥3 of the basic features of pruritus: typical morphology and distribution, including flexural lichenification or linearity in adults and facial and extensor involvement in infants and children; chronic or chronically relapsing dermatitis; and personal or family history of atopy (asthma, allergic rhinitis, atopic dermatitis); along with ≥3 of 23 minor features specified in the criteria
    • Have a documented history of inadequate response to treatment with topical medications or require systemic therapies to control their disease
    • Moderate-to-severe AD defined as BSA ≥10%, IGA ≥3, EASI ≥16 and PP-NRS ≥4 at the baseline visit
    EXCLUSION CRITERIA2,3
    • Active forms of other inflammatory skin diseases
    • Prior treatment with any systemic JAK inhibitors
    • Prior treatment with dupilumab and/or a history of hypersensitivity, intolerance, AE, or allergic reaction associated with prior exposure to the excipients of dupilumab
    • Vaccination with, or exposure to, a live or attenuated vaccine within 6 weeks prior to the first dose
    • Participation in other clinical studies involving investigational drug(s) within 8 weeks prior to study entry
    • Uncontrolled, clinically significant laboratory abnormality that could affect study interpretation
    • Any major psychiatric condition
    • Unwillingness to discontinue current AD medications prior to the study
    • Requiring treatment with prohibited medications during the study
    • Medical history of thrombocytopenia, coagulopathy or platelet dysfunction, or Q wave interval abnormalities
    • Presence or history of certain infections, cancers, lymphoproliferative disorders and other medical conditions at the discretion of the investigator
    • Pregnant or breastfeeding women
    • Women of childbearing potential who are unwilling to use contraception
    PRIMARY ENDPOINT – SKIN CLEARANCESignificantly more patients achieved skin clearance with Cibinqo vs placebo1,2​​​​​​​

    In 12 weeks, 70.3% of patients treated with Cibinqo 200 mg achieved EASI-75 vs 27.1% with placebo (P<0.001).1,2

    Proportion of patients achieving EASI-75 (in combination with medicated topical therapy)2
    Scroll left to view table
    EASI-75 at Week 12 no./Total no. (%, 95% CI)
    Cibinqo 200 mg 154/219 (70.3%; 64.3–76.4)
    Cibinqo 100 mg 138/235 (58.7%; 52.4–65.0)
    Dupilumab 140/241 (58.1%; 51.9–64.3)
    Placebo 35/129 (27.1%; 19.5–34.8)

    EASI-75 response is defined as a 75% improvement in EASI score from baseline.
    ​​​​​​​Analyses shown are between Cibinqo and placebo. Results are not to be interpreted as evidence of superiority, noninferiority, or similarity between Cibinqo and dupilumab

    For most patients, particularly those with severe disease, the recommended starting dose is 200 mg.

    In 12 weeks, 48.4% of patients treated with Cibinqo 200 mg achieved IGA 0/1 vs 14.0% with placebo (P<0.001).1,2

    Proportion of patients achieving IGA 0/1 (in combination with medicated topical therapy)2​​​​​​​
    Scroll left to view table
    IGA 0/1 at Week 12 no./Total no. (%, 95% CI)
    Cibinqo 200 mg 106/219 (48.8%; 41.8–55.0
    Cibinqo 100 mg 86/235 (36.6%; 30.4–42.8)
    Dupilumab 300 mg 88/241 (36.5%; 30.4–42.6)
    Placebo 18/129 (14.0%; 8.0–19.9)
     
    ​​​​​​​IGA response is defined as an IGA score of 0 or 1 and a ≥2-point improvement from baseline.
    ​​​​​​​Analyses shown are between Cibinqo and placebo. Results are not to be interpreted as evidence of superiority, noninferiority, or similarity between Cibinqo and dupilumab
     
    KEY SECONDARY ENDPOINT – ITCH REDUCTIONRapid itch relief with Cibinqo 200 mg vs dupilumab at Week 21,2​​​​​​​

    Cibinqo 200 mg was superior to dupilumab at Week 2 in the proportion of patients achieving PP-NRS4, with significantly higher itch response* seen as early as Day 4 after the first dose.1,2

    • 49.1% (111/226) of patients achieved PP-NRS4 with Cibinqo 200 mg at Week 2
    Proportion of patients achieving PP-NRS4 (combination therapy)1–3​​​​​​​

    *PP-NRS4 is defined as an improvement of ≥4 points from baseline in the severity of PP-NRS. Cibinqo 200 mg was compared with dupilumab in the key secondary head-to-head endpoint, PP-NRS4 at Week 2. This endpoint was further analysed as prespecified multiplicity-controlled analysis and showed superiority to dupilumab down to Day 4.

    SECONDARY ENDPOINT – SKIN CLEARANCEHelp your patients achieve a higher threshold of skin clearance, EASI-901,3

    46.1% (101/219) of patients achieved EASI-90 with Cibinqo 200 mg.

    Proportion of patients achieving EASI-90 (in combination with medicated topical therapy)1,3
    Scroll left to view table
    PP-NRS4 at Week 12 no./Total no. (%, 95% CI)
    Cibinqo 200 mg 101/219 (46.1%; 39.5–52.7)
    Cibinqo 100 mg 86/235 (36.6%; 30.4–42.8)
    Dupilumab 300 mg
    84/241 (34.9%; 28.8–40.9)
    Placebo 13/129 (10.1%; 4.9–15.3)

    EASI-90 is defined as a 90% improvement in EASI score from baseline.
    Data limitations: EASI-90 at all scheduled points are prespecified secondary endpoints not controlled for multiplicity; treatment differences could represent chance findings.
    Analyses shown are between Cibinqo and placebo. Results are not to be interpreted as evidence of superiority, noninferiority, or similarity between Cibinqo and dupilumab.

    SECONDARY ENDPOINT – PATIENT REPORTED OUTCOMESCibinqo demonstrated a greater improvement in the frequency of patient-reported AD symptoms at Week 12 vs placebo1,3

    7.5 point greater improvement in POEM scores reported with Cibinqo 200 mg vs placebo at Week 12 (nominal P<0.0001).

    POEM outcomes at Week 12 (in combination with medicated topical therapy)1,3

    Data limitations: Change from baseline in POEM is a prespecified secondary endpoint not controlled for multiplicity; therefore treatment differences could represent chance findings.
    Analyses shown are between Cibinqo and placebo. Results are not to be interpreted as evidence of superiority, noninferiority, or similarity between Cibinqo and dupilumab.

    Cibinqo demonstrated improvement in patient-reported health-related quality of life at Week 121,3

    86.4% (190/220) of patients reported at least a 4-point improvement in DLQI score with Cibinqo 200 mg at Week 12.

    DLQI outcomes at Week 12 (in combination with medicated topical therapy)1,3

    Data limitations: Change from baseline in DLQI is a prespecified secondary endpoint not controlled for multiplicity; therefore treatment differences could represent chance findings.
    Analyses shown are between Cibinqo and placebo. Results are not to be interpreted as evidence of superiority, noninferiority, or similarity between Cibinqo and dupilumab.

    Cibinqo demonstrated improved patient-reported sleep disruption compared with placebo at Week 121,3

    62.4% greater improvement in reported SCORAD sleep loss subscale with Cibinqo 200 mg vs placebo at Week 12 (nominal P≤0.0001).

    SCORAD sleep loss subscale at Week 12 (in combination with medicated topical therapy)1,3

    SCORAD sleep loss subscale is a component of the SCORAD questionnaire.
    Data limitations: Change from baseline in SCORAD sleep loss is a prespecified secondary endpoint not controlled for multiplicity; therefore treatment differences could represent chance findings.
    Analyses shown are between Cibinqo and placebo. Results are not to be interpreted as evidence of superiority, noninferiority, or similarity between Cibinqo and dupilumab.

    Explore moreSafety

    3,128 patients were treated with Cibinqo in clinical studies in AD representing 2,089 patient-years of exposure.1

    View safety guidanceLoading
    • References: 1. Cibinqo (abrocitinib) Summary of Product Characteristics.

    Dosing

    Learn more about flexible dosing in patients on Cibinqo.

    Discover oral once-daily dosingLoading

    ​​​​​​​AD=atopic dermatitis; AE=adverse event; BSA=body surface area; CI=confidence interval; DLQI​​​​​​​=Dermatology Life Quality Index; EASI=Eczema Area and Severity Index; IGA=Investigator’s Global Assessment; LSM=least squares mean; JAK=Janus kinase; OD=once daily; PDE4=Type 4 cyclic nucleotide phosphodiesterase; POEM=Patient-Oriented Eczema Measure; PP-NRS=Peak Pruritus Numerical Rating Scale; SCORAD=SCORing Atopic Dermatitis; SD=standard deviation.

    Prescribing information:
    Cibinqo (abrocitinib) Prescribing Information (Great Britain) – 200 mg film-coated tablets.
    Cibinqo (abrocitinib) Prescribing Information (Great Britain) – 100 mg film-coated tablets.
    Cibinqo (abrocitinib) Prescribing Information (Great Britain) – 50 mg film-coated tablets.

    References:

    Cibinqo (abrocitinib) Summary of Product Characteristics.Bieber T, et al. N Eng J Med 2021;384:1101–1112.Bieber T, et al. N Eng J Med 2021;384:1101–1112 Supplementary appendix.
    PP-CIB-GBR-0062. November 2021

    Cibinqo Risk Minimisation Programme (RMP) materials, including a Patient Card and Prescriber Brochure, are available from https://www.medicines.org.uk/emc. Patients treated with Cibinqo should be given the Patient Card.

    Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search 

    for MHRA Yellow Card in Google Play or Apple App Store


    Adverse events should also be reported to Pfizer Medical Information on 01304 616161

    PfizerPro Account

    To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.

    Sign In or RegisterAccountSign Out

    This site is intended only for healthcare professionals resident in the United Kingdom. If you are a member of the public wishing to access information on a specific medicine, please visit www.medicines.org.uk/emc


    This website is brought to you by Pfizer Limited, a company registered in England 

    and Wales under No. 526209 with its registered office at Ramsgate Road, Sandwich, Kent, CT13 9NJ


    Copyright © 2021 Pfizer Limited. All rights reserved.


    VAT registration number GB201048427

    PP-PFE-GBR-3849. November 2021

    Add indication message here. It can link a link,
    and you can EMBOLDEN text

    OK, We will need you to sign in before we can determine if you are aligned with a Pfizer promotional colleague.

    If you have already registered with pfizerpro.co.uk and select ‘yes’, you will be directed to the sign-in page where you will be required to enter your username and password.

    Would you like to register or sign in now?

    You are now leaving PfizerPro
    ​​​​​​​You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned or controlled by Pfizer Ltd. 

    ​​​​​​​Pfizer accepts no responsibility for the content or services of the linked site.​​​​​​​​​​​​​​

    ​​​​​​​PP-PFE-GBR-3858. November 2021​​​​​​​
    ​​​​​​​
    For UK Healthcare Professionals *

    These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

    I confirm that I am a healthcare professional* resident in the United Kingdom.

    If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.

    *The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

    PP-PFE-GBR-3863. November 2021

    Yes No
    You are now leaving PfizerPro
    ​​​​​​​You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned nor controlled by Pfizer Ltd. 

    Pfizer accepts no responsibility for the content or services of the linked site other than the information or other materials relating to ​​​​​Pfizer medicines or 
    business which it has provided or reviewed.

    PP-PFE-GBR-3859. November 2021
    ​​​​​​​